Stock OPKO HEALTH INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Opko Health Inc. Nyse

Equities

US68375N1037

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Opko Health Inc.
Mar. 28 Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets MT
Mar. 20 Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
InvestorBrandMedia: Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM) Amidst Groundbreaking Cancer Therapy Innovations
AQ
Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets
MT
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
AQ
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
CI
OPKO Health : Immediate Report
PU
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing
MT
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing
MT
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing
MT
OPKO Health - AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
AQ
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
AQ
OPKO Health : Immediate Report
PU
OPKO Health : Report of Periodic or Interim Report
PU
Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating
MT
OPKO Health: Q4 Earnings Snapshot
AQ
Transcript : OPKO Health, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M
MT
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
AQ
Drugmakers deepen efforts to tap into booming market for obesity drugs
RE
Thinking about buying stock in Intuitive Machines, OPKO Health, Ardelyx, AXT Inc, or Clearmind Medicine?
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OPK Stock
  4. Stock
  5. News Opko Health Inc.